Is CNO a Buy? What to Consider in 2026

Last updated July 2026

Short answer

The bull case for CNO Financial Group provides life and health insurance (CNO) rests on Middle-income and senior market focus: CNO targets a large, underserved segment of Americans who are often overlooked by larger insurers and wealth managers. Revenue (TTM) is ~$4.1B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: CNO carries the typical risks of a life and health insurer. Whether CNO is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.

CNO Financial Group provides life and health insurance, annuities, and workforce benefits to middle-income and senior consumers across the United States. It reaches customers through a mix of career agents (Bankers Life), worksite and independent distribution (Washington National and Optavise), and direct-to-consumer channels (Colonial Penn, known for its television-advertised life policies). The company reports roughly 3.3 million policies and about $39 billion in total assets, and organizes its business around three main insurance segments plus a fee-based benefits arm. The investment picture is that of a stable, capital-return-focused insurer. CNO has posted a long streak of new-sales growth (15 consecutive quarters as of Q1 2026), grown operating earnings per share at a double-digit pace, and raised its dividend for 14 straight years while buying back stock. As a life-and-health insurer, its results are sensitive to interest rates, investment-portfolio credit quality, and the performance of legacy long-term-care blocks. Investors typically weigh its low valuation and consistent capital return against the slower structural growth of the middle-income insurance market.

What's the case for buying CNO?

1. Middle-income and senior market focus

CNO targets a large, underserved segment of Americans who are often overlooked by larger insurers and wealth managers. Aging demographics support demand for Medicare supplement, supplemental health, final-expense life and annuity products. This niche gives CNO a defensible distribution position through career and worksite agents.

2. Consistent sales and earnings momentum

The company has reported multiple consecutive quarters of new annualized premium growth and double-digit operating EPS gains. Q1 2026 operating EPS rose about 33% year over year, and full-year 2025 operating EPS reached roughly $4.40. Continued agent recruiting and worksite expansion are the main levers for further growth.

3. Capital return and balance-sheet strength

CNO has raised its dividend for 14 consecutive years and regularly returns capital through buybacks, reducing its share count over time. A solid statutory capital position and steady operating cash flow support this program. Book value per share has been growing alongside earnings.

4. Investment income leverage

As an insurer, CNO earns a meaningful portion of profit from its investment portfolio backing policy reserves. Higher reinvestment yields in a higher-rate environment can lift net investment income over time. Portfolio positioning and credit quality are central to sustaining spread income.

What are the risks to CNO?

CNO carries the typical risks of a life and health insurer. Its investment portfolio is exposed to credit losses, and prolonged low or sharply changing interest rates can pressure spread income and reserve adequacy. Legacy long-term-care insurance blocks can require reserve strengthening if claims or assumptions worsen. Margin compression, adverse mortality or morbidity trends, and regulatory or reserving changes can weigh on earnings. As a mid-cap insurer, the stock can also be more sensitive to sentiment shifts than larger, more diversified peers.

How is CNO valued? (as of July 2026)

Price

$53.59

Market cap

$5.00B

P/E (TTM)

21.61

Forward P/E

10.84

Price / book

2.01

Beta

0.82

52-week range

$35.24 to $54.09

Snapshot for CNO as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Market cap: ~$4.9B
Revenue (TTM): ~$4.1B
Net income (FY2025): ~$229M
Operating EPS (FY2025): ~$4.40
Forward P/E: ~12x
Dividend yield: ~1.3%

CNO trades at a modest forward earnings multiple relative to the broader market, consistent with its profile as a mature, mid-cap insurer. It has raised its dividend for 14 consecutive years, with a recent quarterly payout of about $0.17 per share. Total assets are roughly $39 billion backing about 3.3 million policies.

How do you decide if CNO is a buy?

Rather than asking whether CNO is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold CNO indirectly through an index or sector ETF before adding more.

For the full picture, see the CNO stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about CNO against your real portfolio and see your actual exposure before deciding.

The bottom line on CNO

The bottom line: CNO Financial Group provides life and health insurance's story right now is Middle-income and senior market focus, with revenue (ttm) at ~$4.1B. If you believe that narrative continues, the call is about sizing CNO sensibly and checking overlap with what you own; if you doubt it (the risk: cNO carries the typical risks of a life and health insurer.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.

Build a basket around CNO with Walnut

Use CNO Financial Group provides life and health insurance as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.

Create a free Walnut account

FAQ

Is CNO a good stock to buy right now?

The case for CNO Financial Group provides life and health insurance right now is Middle-income and senior market focus, with revenue (ttm) at ~$4.1B. If you believe that thesis holds, CNO is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is cNO carries the typical risks of a life and health insurer. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.

What does CNO Financial Group provides life and health insurance do?

CNO Financial Group provides life and health insurance, annuities, and workforce benefits to middle-income and senior consumers across the United States.

What are the main risks of CNO?

What does CNO Financial Group do?

CNO is an insurance holding company that sells life, health, supplemental and annuity products to middle-income and senior Americans. It operates through the Bankers Life, Washington National, Colonial Penn and Optavise brands, using career agents, worksite distribution and direct-to-consumer channels.

Is CNO Financial a large company?

CNO is a mid-cap company with a market value of roughly $4.9 billion as of July 2026. It reports about $39 billion in total assets and around 3.3 million policies, but it is smaller than the largest diversified life insurers.

Does CNO Financial pay a dividend?

Yes. CNO pays a quarterly cash dividend, recently about $0.17 per share, for a yield near 1.3% as of July 2026. The company has raised its dividend for 14 consecutive years.

How has CNO been performing recently?

CNO reported full-year 2025 operating EPS of roughly $4.40 and continued growth into 2026, with Q1 2026 operating EPS up about 33% year over year. The company has cited a long streak of consecutive quarters of new-sales growth.

Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell CNO; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.